Meta-analysis of gemcitabine versus vinorelbine combined with cisplatin in treatment of advanced non-small cell lung cancer

HE Zhi-gao; BAO Si-wei; ZHAI Xiao-bo

doi:10.3969/j.issn.1006-0111.2012.02.015

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Volume 30 Issue 2

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Practice and Service > 2012 > 30(2): 131-136

HE Zhi-gao, BAO Si-wei, ZHAI Xiao-bo. Meta-analysis of gemcitabine versus vinorelbine combined with cisplatin in treatment of advanced non-small cell lung cancer[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(2): 131-136. doi: 10.3969/j.issn.1006-0111.2012.02.015

Citation:

HE Zhi-gao, BAO Si-wei, ZHAI Xiao-bo. Meta-analysis of gemcitabine versus vinorelbine combined with cisplatin in treatment of advanced non-small cell lung cancer[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(2): 131-136. doi: 10.3969/j.issn.1006-0111.2012.02.015

Meta-analysis of gemcitabine versus vinorelbine combined with cisplatin in treatment of advanced non-small cell lung cancer

doi: 10.3969/j.issn.1006-0111.2012.02.015

Department of pharmacy, Shanghai east hospital, Shanghai 200120, China

Received Date: 2012-02-13
Rev Recd Date: 2012-03-01

Abstract

Objective To compare and evaluate the effectiveness and security of gemcitabine versus vinorelbine combined with cisplatin in treatment of advanced non-small cell lung cancer by Meta-analysis. Methods PubMed database and CHKD database were searched, included in randomized controlled trials. Special software Review Manager Version 4.2.2 was used to systematic reviews. Results Seven studies of English journals involving 1 561 patients and ten studies of Chinese journals involving 864 patients were included. There was no difference in the overall response from gemcitabine versus vinorelbine in combination with cisplatin by Meta-analysis of English and Chinese journals. But the project of gemcitabine+cisplatin was superior to vinorelbine+cisplatin in 1-year survival rate of English journals and there was no difference in 1-year survival rate by Meta-analysis of Chinese journals. Both English and Chinese journals showed the same reports of toxicity. The incidence rate of neutropenia was higher in vinorelbine+cisplatin, and the thrombocytopenia was higher in gemcitabine + cisplatin, nausea and vomiting and nervous system response were no significant difference between two groups. Conclusions The effectiveness of gemcitabine versus vinorelbine combined with cisplatin of advanced non-small cell lung cancer was different. Improving the quality of RCT in Chinese journals was very important.
- advanced non-small cell lung cancer,
- chemotherapy,
- gemcitabine,
- vinorelbine,
- cisplatin,
- Meta-znalysis

References

[1]	Novello S,Le Chevalier T. Chemotherapy for non-small-cell lung cancer. Part 1 :Early-stage disease[J].Oncol (Williston Park),2003,17(3):357.
[2]	Alberti W.Chemotherapy in non-small-cell lung cancer:a meta-analysis using updated data on individual patients from 52 randomized clinical trials Non-small Cell Lung Cancer Collaborative Group[J].BMJ,1995,311(7010):899.
[3]	Juni P, Altman DG, Egger M.Systematic reviews in health care: Assessing the quality of controlled clinical trials[J].BMJ,2001,323(7303):42.
[4]	Chang JW,Tsao TC,Yang CT,et al.A randomized study of gemcitabine plus cisplatin and vinorelbine plus cisplatin in patients with advanced non-small-cell lung cancer[J].Chang Gung Med J,2008,31(6):559.
[5]	Comeplla P, Frasci G, Panza N, et al.Randomized trial comparing cisplatin,gemcitabine,and vinorelbine in advanced non-small-cell lung cancer:interim analysis of a phase Ⅲ trial of the Southern Italy Cooperative Oncology Group[J].J Clin Oncol,2000,18(7):1451.
[6]	Gebbia V,Galetta D, Caruso M,et al.Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage ⅢB-Ⅳ non small cell lung carcinoma:a prospective randomized phase Ⅲ trial of the Gruppo Oncologico Italia Meridionale[J].Lung Cancer,2003,9(2):179.
[7]	Gridelli C,Maione P,Illiano A,et al.Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer:the MILES-2P studies[J].J Clin Oncol,2007,25(29):4663.
[8]	Martoni A, Marino A,Sperandi F,et al.Multicentre randomised phase Ⅲ study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer[J].Eur J Cance,2005,1(1):81.
[9]	Novello S,Kielhorn A,Stynes G,et al.Cost-minimisation analysis comparing gemcitabine/cisplatin,paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment advanced non-small cell lung cancer in Italy[J].Lung Cancer,2005,48(3):379.
[10]	Ohe Y,Ohashi Y,Kubota K,et al.Randomized phase Ⅲ study of cisplatin plus irinotecan versus carboplatin plus paclitaxel,cisplatin plus gemcitabine,and cisplatin plus vinorelbine for advanced non-small-cell lung cancer:Four-Arm Cooperative Study in Japan[J].Ann Oncol,2007,18(2):317.
[11]	岳峥,李琳琳.GP方案和NP方案治疗晚期非小细胞肺癌疗效比较[J].实用肿瘤学杂志,2006,20(4):315.
[12]	张英.长春瑞滨联合顺铂治疗晚期非小细胞肺癌的疗效观察[J].临床肺科杂志,2011,16(11):1729.
[13]	时珠海.以顺铂为基础三种化疗方案治疗晚期非小细胞肺癌疗效观察[J].内科,2011,6(4):321.
[14]	赵文英,吉兆宁.顺铂加吉西他滨与顺铂加长春瑞滨一线治疗晚期非小细胞肺癌的对照研究[J].中国临床药理学与治疗学,2006,11(12):1408.
[15]	刘联,王秀问,黎莉,等.含顺铂的三组联合化疗方案治疗晚期非小细胞肺癌的随机对照临床研究[J].癌症,2006,25(8):990.
[16]	陈群,石琴,谢强,等.不同方案治疗晚期非小细胞肺癌的近期疗效观察[J].临床肺科杂志,2008,13(8):998.
[17]	宋昱晨.GP与NP方案治疗晚期非小细胞肺癌的临床对比观察[J].当代医学,2007,(10):68.
[18]	谢强,陈群,李育宏,等.GP和NP方案治疗晚期非小细胞肺癌的随机对照临床研究[J].临床肺科杂志,2008,13(2):160.
[19]	李兆元,黄秋华,徐海声,等.国产吉西他滨或长春瑞滨联合顺铂治疗进展期非小细胞肺癌的临床观察[J].现代肿瘤医学,2007,15(9):1255.
[20]	隋捷,刘积良,段寅,等.吉西他滨联合顺铂治疗晚期非小细胞肺癌的临床研究[J].中国肿瘤临床,2004,31(23):1349.
[21]	胡燕,徐传新.缬沙坦治疗轻、中度原发性高血压有效性与安全性的Meta分析 [J].中国药房,2008,19(2):128.
[22]	何志高,周东,舒丽芯.荟萃分析在头孢三嗪治疗下呼吸道感染中的应用[J].中国药房,2001,12(5):280.
[23]	林晓萍,王庆生.Meta-analysis在肿瘤循证医学中的应用[J].中国肿瘤临床(英文版),2008,5(1):1.

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views(3634) PDF downloads(354) Cited by()

Proportional views

Meta-analysis of gemcitabine versus vinorelbine combined with cisplatin in treatment of advanced non-small cell lung cancer

Department of pharmacy, Shanghai east hospital, Shanghai 200120, China

Received Date: 2012-02-13

Rev Recd Date: 2012-03-01

Key words:

Abstract: Objective To compare and evaluate the effectiveness and security of gemcitabine versus vinorelbine combined with cisplatin in treatment of advanced non-small cell lung cancer by Meta-analysis. Methods PubMed database and CHKD database were searched, included in randomized controlled trials. Special software Review Manager Version 4.2.2 was used to systematic reviews. Results Seven studies of English journals involving 1 561 patients and ten studies of Chinese journals involving 864 patients were included. There was no difference in the overall response from gemcitabine versus vinorelbine in combination with cisplatin by Meta-analysis of English and Chinese journals. But the project of gemcitabine+cisplatin was superior to vinorelbine+cisplatin in 1-year survival rate of English journals and there was no difference in 1-year survival rate by Meta-analysis of Chinese journals. Both English and Chinese journals showed the same reports of toxicity. The incidence rate of neutropenia was higher in vinorelbine+cisplatin, and the thrombocytopenia was higher in gemcitabine + cisplatin, nausea and vomiting and nervous system response were no significant difference between two groups. Conclusions The effectiveness of gemcitabine versus vinorelbine combined with cisplatin of advanced non-small cell lung cancer was different. Improving the quality of RCT in Chinese journals was very important.

HTML

Reference (23)

[1]	Novello S,Le Chevalier T. Chemotherapy for non-small-cell lung cancer. Part 1 :Early-stage disease[J].Oncol (Williston Park),2003,17(3):357.
[2]	Alberti W.Chemotherapy in non-small-cell lung cancer:a meta-analysis using updated data on individual patients from 52 randomized clinical trials Non-small Cell Lung Cancer Collaborative Group[J].BMJ,1995,311(7010):899.
[3]	Juni P, Altman DG, Egger M.Systematic reviews in health care: Assessing the quality of controlled clinical trials[J].BMJ,2001,323(7303):42.
[4]	Chang JW,Tsao TC,Yang CT,et al.A randomized study of gemcitabine plus cisplatin and vinorelbine plus cisplatin in patients with advanced non-small-cell lung cancer[J].Chang Gung Med J,2008,31(6):559.
[5]	Comeplla P, Frasci G, Panza N, et al.Randomized trial comparing cisplatin,gemcitabine,and vinorelbine in advanced non-small-cell lung cancer:interim analysis of a phase Ⅲ trial of the Southern Italy Cooperative Oncology Group[J].J Clin Oncol,2000,18(7):1451.
[6]	Gebbia V,Galetta D, Caruso M,et al.Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage ⅢB-Ⅳ non small cell lung carcinoma:a prospective randomized phase Ⅲ trial of the Gruppo Oncologico Italia Meridionale[J].Lung Cancer,2003,9(2):179.
[7]	Gridelli C,Maione P,Illiano A,et al.Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer:the MILES-2P studies[J].J Clin Oncol,2007,25(29):4663.
[8]	Martoni A, Marino A,Sperandi F,et al.Multicentre randomised phase Ⅲ study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer[J].Eur J Cance,2005,1(1):81.
[9]	Novello S,Kielhorn A,Stynes G,et al.Cost-minimisation analysis comparing gemcitabine/cisplatin,paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment advanced non-small cell lung cancer in Italy[J].Lung Cancer,2005,48(3):379.
[10]	Ohe Y,Ohashi Y,Kubota K,et al.Randomized phase Ⅲ study of cisplatin plus irinotecan versus carboplatin plus paclitaxel,cisplatin plus gemcitabine,and cisplatin plus vinorelbine for advanced non-small-cell lung cancer:Four-Arm Cooperative Study in Japan[J].Ann Oncol,2007,18(2):317.
[11]	岳峥,李琳琳.GP方案和NP方案治疗晚期非小细胞肺癌疗效比较[J].实用肿瘤学杂志,2006,20(4):315.
[12]	张英.长春瑞滨联合顺铂治疗晚期非小细胞肺癌的疗效观察[J].临床肺科杂志,2011,16(11):1729.
[13]	时珠海.以顺铂为基础三种化疗方案治疗晚期非小细胞肺癌疗效观察[J].内科,2011,6(4):321.
[14]	赵文英,吉兆宁.顺铂加吉西他滨与顺铂加长春瑞滨一线治疗晚期非小细胞肺癌的对照研究[J].中国临床药理学与治疗学,2006,11(12):1408.
[15]	刘联,王秀问,黎莉,等.含顺铂的三组联合化疗方案治疗晚期非小细胞肺癌的随机对照临床研究[J].癌症,2006,25(8):990.
[16]	陈群,石琴,谢强,等.不同方案治疗晚期非小细胞肺癌的近期疗效观察[J].临床肺科杂志,2008,13(8):998.
[17]	宋昱晨.GP与NP方案治疗晚期非小细胞肺癌的临床对比观察[J].当代医学,2007,(10):68.
[18]	谢强,陈群,李育宏,等.GP和NP方案治疗晚期非小细胞肺癌的随机对照临床研究[J].临床肺科杂志,2008,13(2):160.
[19]	李兆元,黄秋华,徐海声,等.国产吉西他滨或长春瑞滨联合顺铂治疗进展期非小细胞肺癌的临床观察[J].现代肿瘤医学,2007,15(9):1255.
[20]	隋捷,刘积良,段寅,等.吉西他滨联合顺铂治疗晚期非小细胞肺癌的临床研究[J].中国肿瘤临床,2004,31(23):1349.
[21]	胡燕,徐传新.缬沙坦治疗轻、中度原发性高血压有效性与安全性的Meta分析 [J].中国药房,2008,19(2):128.
[22]	何志高,周东,舒丽芯.荟萃分析在头孢三嗪治疗下呼吸道感染中的应用[J].中国药房,2001,12(5):280.
[23]	林晓萍,王庆生.Meta-analysis在肿瘤循证医学中的应用[J].中国肿瘤临床(英文版),2008,5(1):1.

Message Board

Meta-analysis of gemcitabine versus vinorelbine combined with cisplatin in treatment of advanced non-small cell lung cancer

doi: 10.3969/j.issn.1006-0111.2012.02.015

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views